Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
TYK Medicines, Inc. Class H ( (HK:2410) ) has provided an announcement.
TYK Medicines, Inc has announced the appointment of Mr. Jiang Xiaolin as an independent non-executive director and chairman of the audit committee, effective December 12, 2025. This strategic move is part of a broader change in the composition of the board committees, which also includes the appointment of Dr. GU Eric Hong to the audit committee and the departure of Dr. LI Jun from the same. These changes are expected to strengthen the company’s governance and compliance with Hong Kong listing rules, potentially impacting its operational efficiency and stakeholder confidence.
The most recent analyst rating on (HK:2410) stock is a Buy with a HK$31.60 price target. To see the full list of analyst forecasts on TYK Medicines, Inc. Class H stock, see the HK:2410 Stock Forecast page.
More about TYK Medicines, Inc. Class H
TYK Medicines, Inc is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on the development and distribution of medicinal products, aiming to enhance its market presence through strategic appointments and compliance with regulatory standards.
Average Trading Volume: 8,621,970
Technical Sentiment Signal: Sell
Current Market Cap: HK$4.91B
For detailed information about 2410 stock, go to TipRanks’ Stock Analysis page.